首页> 外文期刊>Arthritis research & therapy. >Comparative analysis of collagen type II-specific immune responses during development of collagen-induced arthritis in two B10 mouse strains
【24h】

Comparative analysis of collagen type II-specific immune responses during development of collagen-induced arthritis in two B10 mouse strains

机译:两种B10小鼠品系胶原诱导的关节炎发展过程中II型胶原特异性免疫反应的比较分析

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction: Immune responses against collagen type II (CII) are crucial for the development of collagen-induced arthritis (CIA). The aim of the present study was to evaluate and compare the CII-directed T cell and antibody specificity at different time points in the course of CIA using two mouse strains on the B10 genetic background - B10.Q, expressing AqMHC class II molecules, and B10.DR4.Ncf1*/*, expressing human rheumatoid arthritis-associated MHC II DR4 molecules (DRA*0101/DRB*0401).Methods: B10.Q and B10.DR4.Ncf1*/*mice were immunized with CII emulsified in adjuvant and development of CIA was assessed. T cells from draining lymph nodes were restimulated in vitro with CII peptides and interferon-gamma (IFN-γ) levels in culture supernatants were evaluated by ELISA. CII-specific antibody levels in serum samples were measured by ELISA.Results: At four different CIA time points we analyzed T cell specificity to the immunodominant CII epitope 259-273 (CII259-273) and several posttranslationally modified forms of CII259-273 as well as antibody responses to three B cell immunodominant epitopes on CII (C1, U1, J1). Our data show that CII-specific T and B cell responses increase dramatically after disease onset in both strains and are sustained during the disease course. Concerning anti-CII antibody fine specificity, during all investigated stages of CIA the B10.Q mice responded predominantly to the C1 epitope, whereas the B10.DR4.Ncf1*/*mice also recognized the U1 epitope. In the established disease phase, T cell reactivity toward the galactosylated CII259-273 peptide was similar between the DR4- and the Aq-expressing strains whereas the response to the non-modified CII peptide was dramatically enhanced in the DR4 mice compared with the B10.Q. In addition, we show that the difference in the transgenic DR4-restricted T cell specificity to CII259-273 is not dependent on the degree of glycosylation of the collagen used for immunization.Conclusions: The present study provides important evaluation of CII-specific immune responses at different phases during CIA development as well as a comparative analysis between two CIA mouse models. We indicate significant differences in CII T cell and antibody specificities between the two strains and highlight a need for improved humanized B10.DR4 mouse model for rheumatoid arthritis.
机译:简介:对II型胶原(CII)的免疫反应对于胶原诱导的关节炎(CIA)的发展至关重要。本研究的目的是使用两种表达AqMHC II类分子的B10遗传背景B10.Q小鼠品系,评估和比较CIA过程中不同时间点的CII定向T细胞和抗体特异性。表达人类风湿关节炎相关MHC II DR4分子(DRA * 0101 / DRB * 0401)的B10.DR4.Ncf1 * / *。方法:用在C10中乳化的CII免疫小鼠B10.Q和B10.DR4.Ncf1 * / *。评估了CIA的佐剂和发展。用CII肽在体外对引流淋巴结的T细胞进行再刺激,并通过ELISA评估培养上清液中的干扰素-γ(IFN-γ)水平。结果:在四个不同的CIA时间点,我们分析了T细胞对免疫优势CII表位259-273(CII259-273)以及几种翻译后修饰形式的CII259-273的T细胞特异性。作为对CII(C1,U1,J1)上三个B细胞免疫显性表位的抗体反应。我们的数据表明,两种菌株在发病后,CII特异性的T和B细胞反应均显着增加,并且在病程中持续存在。关于抗CII抗体的优良特异性,在CIA的所有研究阶段中,B10.Q小鼠主要对C1表位作出反应,而B10.DR4.Ncf1 * / *小鼠也识别U1表位。在已确定的疾病阶段,DR4-和表达Aq的菌株对半乳糖基化的CII259-273肽的T细胞反应性相似,而与B10相比,DR4小鼠对未修饰的CII肽的反应显着增强。问此外,我们表明转基因DR4限制的T细胞对CII259-273的特异性差异不取决于用于免疫的胶原蛋白的糖基化程度。结论:本研究为CII特异性免疫反应提供了重要的评估在CIA发育期间的不同阶段,以及两种CIA小鼠模型之间的比较分析。我们表明这两种菌株之间在CII T细胞和抗体特异性上有显着差异,并突出显示了对类风湿性关节炎改良人源化B10.DR4小鼠模型的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号